II. Indications
- Pneumonia
- Pyelonephritis
- Pelvic Inflammatory Disease
- Sepsis
- Neonatal Sepsis
- Meningitis
- Skin and Soft Tissue Infections
- Bone and Joint Infections
- Intraabdominal infections
- Gonorrhea
III. Mechanism
- See Third Generation Broad-Spectrum Cephalosporin
- Cefotaxime has the more Staphylococcus Aureus and Anaerobic activity than Ceftriaxone
IV. Dosing
- Precautions
- Bolus dosing via Central Line risks Arrhythmia
- Adult
- Standard
- Give 1 to 2 g IM or IV every 12 hours (every 8 hours in severe infections)
- High Dose (Life threatening infections or Meningitis)
- Give 2 g IV every 4 to 6 hours
- Standard
- Child
- Newborns
- Give 50 mg/kg/dose IV every 12 hours for age <7 days
- Give 50 mg/kg/dose IV every 8 hours for age 1 to 4 weeks
- Mild to Moderate Infections
- Give 75 to 100 mg/kg/day IM or IV divided 6 to 8 hours
- Severe Infections
- Give 150 to 200 mg/kg/day IM or IV divided 6 to 8 hours
- Meningitis (for Streptococcus Pneumoniae)
- Give 225 to 300 mg/kg/day IV divided every 6 to 8 hours
- Maximum
- Limit to 2 g/dose
- Newborns
-
Renal Dosing
- eGFR <20 ml/min: Decrease usual dose by 50%
V. Safety
- Pregnancy Category B
- Safe in Lactation
VI. Resources
VII. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
- (2012) Presc Lett, Resource #280706, Comparison of Cephalosporins
Images: Related links to external sites (from Bing)
Related Studies
| Definition (NCI) | A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. |
| Definition (MSH) | Semisynthetic broad-spectrum cephalosporin. |
| Definition (PDQ) | A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39177&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39177&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C354" NCI Thesaurus) |
| Concepts | Antibiotic (T195) , Organic Chemical (T109) |
| MSH | D002439 |
| SnomedCT | 3334000, 372704003 |
| LNC | LP14831-9, MTHU002074 |
| English | Cefotaxim, Cefotaxime, Cephotaxim, 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, monosodium salt, (6R-(6alpha,7beta(Z)))-, cefotaxime (medication), Cefotaxime [Chemical/Ingredient], cefotaxim, cefotaxime, CEFOTAXIME, Cefotaxime product, Cefotaxime (product), Cefotaxime (substance) |
| Swedish | Cefotaxim |
| Czech | cefotaxim |
| Finnish | Kefotaksiimi |
| Russian | TSEFOTAKSIM, ЦЕФОТАКСИМ |
| Japanese | セフォタキシム |
| Croatian | CEFOTAKSIM |
| Polish | Cefotaksym |
| Spanish | cefotaxima (producto), cefotaxima (sustancia), cefotaxima, Cefotaxima |
| French | Céfotaxime |
| German | Cefotaxim |
| Italian | Cefotaxima |
| Portuguese | Cefotaxima |
Ontology: Claforan (C0701052)
| Concepts | Antibiotic (T195) , Organic Chemical (T109) |
| MSH | D002439 |
| English | Claforan ADD-Vantage, claforan, Claforan, Klaforan, Aventis Brand of Cefotaxime Sodium, Aventis Pharma Brand of Cefotaxime Sodium, Hoechst Brand of Cefotaxime Sodium, Primafen |
